A detailed history of Hollencrest Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hollencrest Capital Management holds 295 shares of VRTX stock, worth $117,194. This represents 0.01% of its overall portfolio holdings.

Number of Shares
295
Previous 295 -0.0%
Holding current value
$117,194
Previous $138,000 0.72%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $39,281 - $48,553
100 Added 51.28%
295 $138,000
Q1 2024

May 01, 2024

SELL
$407.69 - $446.08 $390,159 - $426,898
-957 Reduced 83.07%
195 $81,000
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $61,397 - $73,511
179 Added 18.4%
1,152 $468,000
Q1 2023

May 16, 2023

BUY
$283.23 - $323.1 $271,051 - $309,206
957 Added 5981.25%
973 $306,000
Q4 2022

Feb 06, 2023

BUY
$285.76 - $321.48 $4,572 - $5,143
16 New
16 $4,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hollencrest Capital Management Portfolio

Follow Hollencrest Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hollencrest Capital Management with notifications on news.